TOP
닫기
Search 닫기
Advanced Search Quick links
· Most Cited · Most Read · On-line First · Archives · Go to e-Submission

Minireview

Split Viewer

Mol. Cells 2021; 44(5): 301-309

Published online May 11, 2021

https://doi.org/10.14348/molcells.2021.0053

© The Korean Society for Molecular and Cellular Biology

Innate Lymphoid Cells in Tissue Homeostasis and Disease Pathogenesis

Jihyun Kim1,2 , Seungwon Ryu1 , and Hye Young Kim1,2, *

Author Info. +

1Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea, 2Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 03080, Korea

Correspondence to : hykim11@snu.ac.kr

Received: March 6, 2021; Revised: March 30, 2021; Accepted: March 30, 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.

Abstract

Go to

Innate lymphoid cells (ILCs) are the most recently discovered family of innate immune cells. ILCs can be categorized into three groups on the basis of the transcription factors that direct their functions and the cytokines they produce. Notably, these functions parallel the effector functions of T lymphocytes. ILCs play a frontline role in host defense and tissue homeostasis by responding rapidly to environmental factors, conducting effector responses in a tissue-specific manner, and interacting with hematopoietic and non-hematopoietic cells throughout the body. Moreover, recent studies reveal that ILCs are involved in development of various inflammatory diseases, such as respiratory diseases, autoimmune diseases, or cancer. In this review, we discuss the recent findings regarding the biology of ILCs in health and inflammatory diseases.

Keywords development, homeostasis, inflammation, innate lymphoid cells, plasticity, tropism

INTRODUCTION

Go to

Innate lymphoid cells (ILCs) are recently identified lymphocytes that lack antigen-specific receptors but have similar functions as T cells and thus serve as the innate counterparts to T cells (Diefenbach et al., 2014; Spits and Cupedo, 2012). They respond quickly to signals from the tissue environment and are in general enriched in barrier tissues (i.e., skin, lung, and intestine) rather than in lymphoid tissues. There are three ILC subsets, each of which displays a distinct predilection for particular tissues. Within these tissues, the ILCs play specific roles in homeostasis and disease (Mjösberg and Eidsmo, 2014; Patman, 2015) that will be discussed in this review.

INNATE LYMPHOID CELLS

Go to

ILC subsets

Unlike lineage cells such as T cells, B cells, and myeloid cells, ILCs do not express lineage markers (Vivier et al., 2018). Instead, they can be divided into three groups (group 1 ILCs, group 2 ILCs, and group 3 ILCs) on the basis of the cytokines they produce and the master regulatory transcription factors that drive their development and functions.

Group 1 ILCs include ILC1s and natural killer cells (NK cells). They express CD161 and interleukin (IL)-12 receptor beta (IL-12Rβ) on their surface, and their master transcription factor is T-bet (Cortez and Colonna, 2016; O'Sullivan, 2019). ILC1s are the innate counterpart to Th1 cells since they secrete interferon γ (IFNγ) and tumor necrosis factor α (TNFα), while NK cells are considered to be the innate counterpart to type 1 cytotoxic T (Tc1) cells since they produce TNFα, IFNγ, perforin, and granzyme.

Group 2 ILCs (ILC2s) express the IL-33 receptor (IL-33R) and the transcription factors GATA binding protein 3 (GATA3) and RAR-related orphan receptor alpha (RORα) (Entwistle et al., 2020). ILC2s are the counterparts to Th2 cells because they produce large amounts of type 2 cytokines such as IL-5 and IL-13. ILC2s also express other cytokines, including amphiregulin, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-9 (Morita et al., 2016).

Group 3 ILCs are subdivided into three populations according to their expression of C-C motif chemokine receptor 6 (CCR6) and natural cytotoxicity receptors (NCR) (i.e., NKp46 in mice and NKp44 in humans). Thus, the CCR6+ cells are designated LTi; these cells produce lymphotoxins (LT). The CCR6- cells are divided further into NCR+ ILC3s and NCR- ILC3s (Montaldo et al., 2015). ILC3s typically express IL-1 and IL-23 receptors and the RORγt and aryl-hydrocarbon receptor (AhR) transcription factors (Meininger et al., 2020).

Recently, several groups identified a new subset of ILCs, namely, IL-10-producing regulatory ILCs (ILCregs) (Golebski et al., 2021; Morita et al., 2019; Wang et al., 2017). Wang et al. showed that they express a distinct transcription factor, namely, ID3 (inhibitor of DNA binding 3), and that autocrine transforming growth factor beta (TGF-β) signaling is important for their development (Wang et al., 2017). However, other groups have also reported that ILCregs can be derived from ILC2s by retinoic acid (RA) (Golebski et al., 2021; Morita et al., 2019). Further studies on the origin and functions of ILCregs are required.

Development and differentiation of ILCs

ILCs develop from common lymphoid progenitors (CLPs) in the fetal liver and the adult bone marrow (Zook and Kee, 2016). In the mouse, the differentiation of CLPs into mature ILC subsets is regulated by the coordinated expression of a variety of transcription factors that activate or repress critical target genes. These transcription factors include ID2, NFIL3, promyelocytic leukemia zinc finger (PLZF) (encoded by Zbtb16), TCF1 (encoded by Tcf7), and GATA3 (Eberl et al., 2015; Vivier et al., 2018) (Fig. 1). NFIL3 plays a particularly important role since it controls ID2, GATA3, EOMES, and T-bet and thereby orchestrates ILC differentiation (Gascoyne et al., 2009; Male et al., 2014; Xu et al., 2015). The transcriptional ILC differentiation program starts with CLPs expressing NFIL3 and TCF1; this causes them to differentiate into early innate lymphoid progenitors (EILPs), which are the lineage-committed cells for ILCs and NK cells (Geiger et al., 2014; Tanriver and Diefenbach, 2014). The EILPs then differentiate into common helper ILC precursors (CHILPs) due to ID2 and GATA3 expression (Serafini et al., 2014; Tanriver and Diefenbach, 2014; Yagi et al., 2014). Subsequently, PLZF expression drives the development of ILC precursors (ILCp) from CHILPs (Constantinides et al., 2014; 2015). The ILCp exits the fetal liver or adult bone marrow and then circulate in the blood (Eberl et al., 2015). There is also evidence that some ILCp matures in the bone marrow before entering the bloodstream (Eberl et al., 2015; Walker et al., 2019).

Tissue tropism of ILCs

A growing body of evidence suggests that ILC subsets are strategically localized in specific tissues in a way that relates to their roles in immune responses (Bando et al., 2015; Kim et al., 2016a). Thus, ILC1s are largely located in the intraepithelium of the intestine (Fuchs et al., 2013); ILC2s predominate in the lung, skin, and white adipose tissue; and ILC3s are a major population in the lamina propria, cryptopatches, and Peyer’s patches of the intestinal tract (Klose et al., 2013; Luci et al., 2009). This tissue tropism is determined in part by the tissues, which present a signature array of adhesion molecules and emit chemokines, and in part by the ILCp and mature ILCs, which express characteristic homing receptors, including integrins and chemoattractant receptors, that cause them to migrate from the circulation into the peripheral tissues (Lapidot et al., 2005). For example, ILCp expresses integrin α4β7 (Constantinides et al., 2014; Possot et al., 2011) while endothelial cells express the binding partners of α4β7, namely, mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and vascular cell adhesion protein 1 (VCAM-1) at high levels (Deem and Cook-Mills, 2004; Erle et al., 1994). The encounter between ILCp and MAdCAM-1- and VCAM-1-positive endothelium causes the ILCp to stick and then extravasate into the tissue. Thus, α4β7 guides ILCp to mucosal and non-mucosal tissues. Similarly, the ILCp expresses chemokine receptors that guide their migration towards the corresponding chemokines emitted by the tissues. These chemokine receptors include C-X-C motif chemokine receptor 6 (CXCR6), which seems to play an important role in the emigration of ILCp from the bone marrow and their peripheral seeding, and CCR7 and CCR9, which are key gut-homing receptors on ILCs (Chea et al., 2015; Kim et al., 2015; Patman, 2015; Possot et al., 2011; Zlotoff et al., 2010). Thus, by expressing specific homing receptors, ILCp and mature ILCs migrate to specific peripheral tissues (Fig. 2).

ILC plasticity

Once ILCp and mature ILCs enter the tissues, they seem to reside there and proliferate locally. A parabiosis mouse model showed that under homeostatic conditions, ILCs reside in the tissue whereas other lymphocytes circulate through the bloodstream (Gasteiger et al., 2015; Kim et al., 2016a; Moro et al., 2016). In the tissue, ILCp matures into ILC subsets that appear to be shaped by microenvironmental cues (Lim and Di Santo, 2019).

While mature ILCs has less differentiation capacity than ILCp, it is clear that the ILC subtype phenotypes are plastic, meaning they can convert into other subtypes in response to environmental cytokines (Fig. 3). For example, a study that used the genetic fate mapping technique to mark cells showed that stimulating RORγt+ ILC3s with IL-12 and IL-15 increased their expression of T-bet and IFNγ, which is characteristic of ILC1s; this treatment also decreased their expression of RORγt (Bernink et al., 2015; Montaldo et al., 2015). The converse effect is also true: ILC1s can be changed both in vivo and in vitro into ILC3s by IL-2, IL-1β, and IL-23 (Bernink et al., 2015). There is a similar reversible axis of plasticity between ILC2s and ILC1s: ILC2s stimulated in vitro with IL-12 exhibit increased expression of T-bet and IFNγ, and this is reversed by IL-4 (Bal et al., 2016; Lim et al., 2016; Silver et al., 2016). This ILC plasticity highlights the consummate ability of ILCs to sense, communicate with, and adapt to the surrounding microenvironment. As we will see below, these activities of ILCs participate both in tissue homeostasis and inflammation.

ROLES OF ILCS IN TISSUE HOMEOSTASIS

Go to

ILCs help remodel injured tissue in a variety of ways, thereby maintaining tissue integrity. For example, by inducing stromal lymphoid tissue organizer cells to produce chemokines (i.e., C-X-C motif chemokine ligand 13 [CXCL13], CCL21, and CCL19) and adhesion molecules (VCAM-1, MAdCAM-1, and intercellular adhesion molecule 1 [ICAM-1]), the ILC3 subset LTi promotes the formation of secondary lymphoid organs such as Peyer’s patches in the gut, which play an important role in gut homeostasis in the face of microbial colonization and food-derived antigens (van de Pavert et al., 2009). ILC3s also restore secondary lymphoid organs after they have been destroyed by a viral infection (Scandella et al., 2008). Moreover, ILC3s help rehabilitate intestinal epithelium that has been damaged (for example by chemotherapy) by secreting IL-22 (Hazenberg et al., 2019): this induces IL-22 receptor-expressing intestinal stem cells to regenerate the epithelial cells (Wolk et al., 2004). In addition, the intestinal epithelial lesions in dextran sodium sulfate (DSS)-induced colitis can be repaired by ILC2s that have been stimulated with the epithelial cytokine IL-33: these cells produce amphiregulin, which binds to epidermal growth factor receptor (EGFR) on epithelial cells and thereby regulates their differentiation and proliferation (Monticelli et al., 2015). These effects of amphiregulin-expressing ILC2s are also critical for restoring airway epithelial integrity and tissue homeostasis after influenza virus infection (Monticelli et al., 2011). These observations suggest that therapeutically targeting homeostatic ILC responses in tissues could help manage tissue damage.

ILCS IN INFLAMMATORY DISEASES

Go to

The local tissue microenvironment in inflamed tissues can be very different from that in healthy non-inflamed tissues. This can cause ILCs to change their phenotype and functions in both beneficial and pathogenic ways. We discuss below how ILCs act in several inflammatory diseases, namely, asthma, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), and cancer (Fig. 1). It should be noted that despite the essential roles of ILCs in gut homeostasis and tissue repair (see above), these cells also contribute to inflammatory bowel diseases (IBD) and several infectious diseases. For detailed information on ILCs in IBD and infectious diseases, we recommend related excellent reviews (Panda and Colonna, 2019; Peters et al., 2016; Zeng et al., 2019).

Asthma

Asthma is a chronic inflammatory disease that affects about 300 million people worldwide (Beasley and Hancox, 2020). It is characterized by difficulty breathing, coughing, and wheezing that is caused by airway hyperresponseveness (AHR), mucus overproduction, and airway remodeling (Lambrecht and Hammad, 2015). Multiple studies show that ILCs may play key roles in asthma pathogenesis (Kim et al., 2016b; Scanlon and McKenzie, 2012). This was first discovered when allergic asthma models and patients were found to have pulmonary ILC2s that produce large amounts of type 2 cytokines; these cytokines have long been noted to play key pathogenic roles in this classical asthma endotype (Kim et al., 2016b). It is now thought that the pathogenic role of pulmonary ILC2s starts when these cells are activated by various factors that are promptly upregulated in the lungs by allergens: they include the epithelial cytokines IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) and the mast cell factors cysteinyl leukotrienes and prostaglandins (Doherty and Broide, 2019; Liu et al., 2018; Lund et al., 2017; Salimi et al., 2017). The activated ILC2s then recruit other immune cells, including eosinophils and alternatively activated (M2) macrophages; these cells induce AHR and airway inflammation (Halim et al., 2014; Wolterink et al., 2012).

Notably, ILC2s participate in influenza virus-induced asthma in both a pathogenic and a beneficial way. Thus, the virus-damaged epithelial cells secrete IL-33, which stimulates ILC2s and thereby worsens airway inflammation (Chang et al., 2011). On the other hand, the influenza infection stimulates ILC2s to secrete amphiregulin, which causes the damaged epithelial cells to regenerate (Monticelli et al., 2011; Wills-Karp and Finkelman, 2011). ILC2s also play a well-recognized role in the pathology of eosinophilic asthma in humans: patients with severe asthma have increased numbers of ILC2s in their blood and sputum and the disease severity correlates with the amount of type 2 cytokines produced by ILC2s but not the Th2 cells (Liu et al., 2015; Smith et al., 2016). We also found that ILC2s induce the polarization of M2 macrophages in patients with eosinophilic asthma (Kim et al., 2019).

Interestingly, the latter study also showed that in non-eosinophilic asthma, ILC1s and ILC3s, but not ILC2s, activate classically activated (M1) macrophages (Kim et al., 2019). Thus, different types of ILCs may be responsible for the asthma phenotypes in humans. This is supported by studies showing that ILC3s may participate in the non-allergic asthma endotypes that appear to arise independently of Th2 cells (Everaere et al., 2016; Kim et al., 2014); these endotypes include those driven by obesity or environmental factors such as ozone, diesel particles, and cold air (Kim et al., 2010). For example, we observed that when mice were fed a high-fat diet, they spontaneously developed AHR and had significant lung numbers of CCR6+ ILC3s that produced IL-17A, which is a potent neutrophil chemotactic agent. We then showed that these ILC3s were activated and induced to proliferate by IL-1β from M1 macrophages (Kim et al., 2014).

These observations together demonstrate the crucial importance of ILCs in asthma. Further intensive exploration of ILCs is needed since targeting these immune axes could be of therapeutic value.

Chronic obstructive pulmonary disease

COPD includes pulmonary emphysema and chronic bronchitis and is a progressive respiratory disease characterized by long-term breathing problems and obstructed airflow (Rabe and Watz, 2017). The most common risk factor for COPD is smoking. The signature immune responses in this disease are activated neutrophils, macrophages, Th1 cells, Th17 cells, and CD8+ T cells (Bhat et al., 2015; Ni and Dong, 2018).

Although there are fewer studies on COPD than on asthma, several reports suggest that ILCs are also involved in COPD pathogenesis. Kearley et al. showed that chronic exposure to cigarette smoke exacerbates virus-induced lung inflammation and that this associates with a shift away from ILC2 responses to proinflammatory macrophage and NK cell responses using a murine model of virus-induced COPD. Specifically, smoke exposure increases IL-33 secretion from epithelial cells while simultaneously decreasing and increasing IL-33R expression on ILC2s and macrophages/NK cells, respectively (Kearley et al., 2015). Notably, Silver et al. showed that (inflammatory triggers of COPD also provoke pathogenic ILC subset plasticity. They first showed that viral infection and long-term smoking convert ILC2s into ILC1-like populations that express IL-12Rβ2, IL-18 receptor alpha (IL-18Rα), T-bet, and IFNγ. Subsequently, they showed that the severity of COPD correlates with increased ILC1s and decreased ILC2s in the peripheral blood (Silver et al., 2016). The role of ILC3s in COPD is less well studied than the ILC1s and ILC2s, but it has been shown that COPD patients have higher ILC3 frequencies in lung biopsies than control subjects (De Grove et al., 2016). Moreover, COPD lungs, but not unused donor lungs, abundantly express the gene set that relates to the ILC3 subset LTi (Suzuki et al., 2017). Therefore, further studies on the relevance of ILCs, including the ILC3s, in COPD pathogenesis are warranted.

Multiple sclerosis

MS is the most common inflammatory demyelinating disease of the central nervous system (CNS) (Reich et al., 2018). Clinical presentation of MS depends on the location of the demyelinating lesions, leading to its heterogeneous characteristics. It includes sensory or motor symptoms, fatigue, pain, and cognitive decline (Filippi et al., 2018). Since MS is regarded to be a Th17 cell-mediated disease, most of the research on ILCs in MS has focused on the ILC3 subsets. Accordingly, it has been shown that compared to control subjects, patients with MS have higher numbers of ILC3s, including LTi cells, in their cerebrospinal fluid and blood (Degn et al., 2016; Gross et al., 2017). However, when MS patients were treated with Daclizumab, which blocked IL-2 receptor alpha and previously used to treat relapsing MS, their circulating ILC3s (LTi cells) dropped, but NK cells rose. Notably, significant treatment effects were not observed on the frequencies of activated T cells (Perry et al., 2012). These findings suggest that ILC3s contribute to MS pathogenesis. This is supported by studies in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Hatfield and Browns showed that ILC3s are normal resident cells in the meninges (which are where the immune cell infiltration to the CNS starts) and that in EAE, these cells overexpress IFNγ, IL-17, and GM-CSF. This suggests that ILC3s could contribute at an early stage to EAE pathogenesis (Hatfield and Brown, 2015). Moreover, Kwong et al. showed that when encephalitogenic T cells are transferred to T-bet depleted mice, the infiltration of T cells into the CNS is lower than in wildtype mice. It was then shown that the specific loss of T-bet expression in NKp46+ T-bet+ ILCs (i.e., ILC1s or the NKp46+ subset of ILC3s) impairs the ability of the encephalitogenic T cells to invade the CNS (Kwong et al., 2017). These results suggest that despite the fact that ILCs are a minor population in the CNS, they can control the initiation of inflammation in EAE.

Cancer

While cancer is a complex disease, studies in recent years have started to elucidate the roles of ILCs in tumor development. The study of Dadi et al. showed that ILC1s can have anti-tumor effects: when breast cancer arises spontaneously in mice, the mammary glands contain elevated frequencies of ILC1s that bear NK cell characteristics (IFNγ and granzyme B production) and are cytotoxic to tumor cells (Dadi et al., 2016). By contrast, a study with MCA1956 carcinogen-induced sarcoma shows that by expressing TGF-β, tumors can escape NK cell-mediated tumor control by converting cytotoxic NK cells into ILC1s, which are unable to control tumor growth and metastasis (Gao et al., 2017).

The roles of ILC2s in cancer immune response are also controversial. Rag-/- mice challenged with IL-33-expressing B16-melanoma cells develop tumors less effectively than mice challenged with wildtype tumor cells: this is due to the IL-33-mediated expansion and activation of cytotoxic NK cells. However, this beneficial effect of IL-33 is tempered by its effect on ILC2s, which inhibit NK cell activation and cytotoxicity via immunosuppressive enzyme CD73 (Long et al., 2018). Similarly, ILC2s produce IL-13 in the acute promyelocytic leukemia animal model, which activates monocytic myeloid-derived suppressor cells (M-MDSCs) thereby enhances tumor progression (Trabanelli et al., 2017). However, several other studies observe that ILC2s can also have anti-tumor effects. Thus, genetic deletion of ILC2s in mice associates with increased tumor growth and metastasis (Saranchova et al., 2018). Moreover, in pancreatic ductal adenocarcinoma, intratumoral ILC2s activate CD103+ dendritic cells and enhance the anti-tumor responses of CD8+ T cells (Moral et al., 2020). In addition, in a lung metastatic melanoma model, ILC2s produce IL-5, thereby activating eosinophils and increasing their anti-tumor response (Ikutani et al., 2012). Moreover, ILC2s produce IL-9, which is important to suppress metastasis of cancer cells, in tumor microenvironment (Park et al., 2020; Wan et al., 2021).

Similarly, divergent roles were observed for ILC3s. For examples, in models of preclinical breast cancer and invasive colon cancer, ILC3s promote tumor growth and metastasis by producing IL-22 (Irshad et al., 2017; Kirchberger et al., 2013). By contrast, in the B16 melanoma model, NKp46+ ILC3s increase leukocyte invasion and tumor suppression by producing IL-12 and upregulating ICAM-1 and VCAM-1 (Eisenring et al., 2010).

Although studies over the last few years have provided critical insights into the role of ILCs in anti-tumor immune responses, many aspects remain to be explored.

CONCLUSION

Go to

Since ILCs adapt remarkably quickly and fluidly to environmental cues and orchestrate downstream immunity, including adaptive immune responses, they are fundamental front-line defenders of the host. However, because of their sparsity relative to other immune cells, the importance of ILCs has long been underestimated. Since ILCs share many properties with T cells, specific treatment targeting ILCs is not available until now. However, the present review clearly shows that ILCs participate in both tissue homeostasis and disease pathogenesis, thus could be potential therapeutic targets for managing diseases. ILCs might play an important role in priming the immune response at the various stages of the disease by secreting large amounts of cytokines prior to T cells by rapidly responding to alarmins. Therefore, targeting alarmins could be one of the promising approaches to regulating ILCs for disease control, although further experiments are required.

ACKNOWLEDGMENTS

Go to

This study was supported by a grant from the National Research Foundation of Korea (NRF-2019R1A2C2087574) and a grant from the MD-PhD/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI), which was funded by the Ministry of Health & Welfare, Republic of Korea.

FIGURES

Go to
Fig. 1. Development and function of ILCs. ILC differentiation proceeds in a stepwise fashion from hematopoietic stem cells (HSCs) to lymphoid lineage restricted precursors. The development of ILCs from CLPs requires ID2-mediated suppression of alternative lymphoid cell fates that generate B and T cells. CLPs further commit to the ILC/NK lineage via multi‐potent ILCp. Individual subsets depend on the expression of specific transcription factors that determine their terminal differentiation and function. CLP, common lymphoid progenitor; EILP, early innate lymphoid progenitor; CHILP, common helper ILC precursor; NKp, NK cell precursor; ILCp, ILC precursor; LTip, LTi cell precursor.
Fig. 2. Tissue tropism of ILCs. ILCp derived from bone marrow hematopoiesis enters the blood to home to lymphoid and non-lymphoid organs. This process requires the expression of various chemokine receptors and α4β7 integrin. Their strategic position within tissues allows ILCs to act as a monitor of healthy tissue and to enable a rapid response to inflammatory signals. CLP, common lymphoid progenitor; ILCp, ILC precursor.
Fig. 3. Plasticity of ILCs. ILCs exhibit plasticity that can switch between fully polarized subsets to quickly adapt to changes occurring in the environment. The plasticity of ILC1, ILC2, and ILC3 depends on signals from the tissue microenvironment, mainly the cytokine milieu.

REFERENCES

Go to
  1. Bal S.M., Bernink J.H., Nagasawa M., Groot J., Shikhagaie M.M., Golebski K., van Drunen C.M., Lutter R., Jonkers R.E., and Hombrink P., et al. (2016). IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat. Immunol. 17, 636-645.
  2. Bando J.K., Liang H.E., and Locksley R.M. (2015). Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine. Nat. Immunol. 16, 153-160.
    Pubmed KoreaMed CrossRef
  3. Beasley R. and Hancox R.J. (2020). Reducing the burden of asthma: time to set research and clinical priorities. Lancet Respir. Med. 8, 943-944.
    Pubmed CrossRef
  4. Bernink J.H., Krabbendam L., Germar K., de Jong E., Gronke K., Kofoed-Nielsen M., Munneke J.M., Hazenberg M.D., Villaudy J., and Buskens C.J. (2015). Interleukin-12 and-23 control plasticity of CD127+ group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 43, 146-160.
    Pubmed CrossRef
  5. Bhat T.A., Panzica L., Kalathil S.G., and Thanavala Y. (2015). Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 12(Suppl 2), S169-S175.
    Pubmed KoreaMed CrossRef
  6. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., McKenzie A.N., Smith D.E., Dekruyff R.H., and Umetsu D.T. (2011). Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631-638.
    Pubmed KoreaMed CrossRef
  7. Chea S., Possot C., Perchet T., Petit M., Cumano A., and Golub R. (2015). CXCR6 expression is important for retention and circulation of ILC precursors. Mediators Inflamm. 2015, 368427.
    Pubmed KoreaMed CrossRef
  8. Constantinides M.G., Gudjonson H., McDonald B.D., Ishizuka I.E., Verhoef P.A., Dinner A.R., and Bendelac A. (2015). PLZF expression maps the early stages of ILC1 lineage development. Proc. Natl. Acad. Sci. U. S. A. 112, 5123-5128.
    Pubmed KoreaMed CrossRef
  9. Constantinides M.G., McDonald B.D., Verhoef P.A., and Bendelac A. (2014). A committed precursor to innate lymphoid cells. Nature 508, 397-401.
    Pubmed KoreaMed CrossRef
  10. Cortez V.S. and Colonna M. (2016). Diversity and function of group 1 innate lymphoid cells. Immunol. Lett. 179, 19-24.
    Pubmed KoreaMed CrossRef
  11. Dadi S., Chhangawala S., Whitlock B.M., Franklin R.A., Luo C.T., Oh S.A., Toure A., Pritykin Y., Huse M., and Leslie C.S., et al. (2016). Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365-377.
    Pubmed KoreaMed CrossRef
  12. De Grove K.C., Provoost S., Verhamme F.M., Bracke K.R., Joos G.F., Maes T., and Brusselle G.G. (2016). Characterization and quantification of innate lymphoid cell subsets in human lung. PLoS One 11, e0145961.
    Pubmed KoreaMed CrossRef
  13. Deem T.L. and Cook-Mills J.M. (2004). Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 104, 2385-2393.
    Pubmed KoreaMed CrossRef
  14. Degn M., Modvig S., Dyring-Andersen B., Bonefeld C.M., Frederiksen J.L., Geisler C., and von Essen M.R. (2016). Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis. Mult. Scler. 22, 1013-1020.
    Pubmed CrossRef
  15. Diefenbach A., Colonna M., and Koyasu S. (2014). Development, differentiation, and diversity of innate lymphoid cells. Immunity 41, 354-365.
    Pubmed KoreaMed CrossRef
  16. Doherty T.A. and Broide D.H. (2019). Airway innate lymphoid cells in the induction and regulation of allergy. Allergol. Int. 68, 9-16.
    Pubmed KoreaMed CrossRef
  17. Eberl G., Colonna M., Di Santo J.P., and McKenzie A.N. (2015). Innate lymphoid cells: a new paradigm in immunology. Science 348, aaa6566.
    Pubmed KoreaMed CrossRef
  18. Eisenring M., vom Berg J., Kristiansen G., Saller E., and Becher B. (2010). IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 1030-1038.
    Pubmed CrossRef
  19. Entwistle L.J., Gregory L.G., Oliver R.A., Branchett W.J., Puttur F., and Lloyd C.M. (2020). Pulmonary group 2 innate lymphoid cell phenotype is context specific: determining the effect of strain, location, and stimuli. Front. Immunol. 10, 3114.
    Pubmed KoreaMed CrossRef
  20. Erle D.J., Briskin M.J., Butcher E.C., Garcia-Pardo A., Lazarovits A.I., and Tidswell M. (1994). Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J. Immunol. 153, 517-528.
    Pubmed
  21. Everaere L., Ait-Yahia S., Molendi-Coste O., Vorng H., Quemener S., LeVu P., Fleury S., Bouchaert E., Fan Y., and Duez C., et al. (2016). Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. J. Allergy Clin. Immunol. 138, 1309-1318.e11.
    Pubmed CrossRef
  22. Filippi M., Bar-Or A., Piehl F., Preziosa P., Solari A., Vukusic S., and Rocca M.A. (2018). Multiple sclerosis. Nat. Rev. Dis. Primers 4, 43.
    Pubmed CrossRef
  23. Fuchs A., Vermi W., Lee J.S., Lonardi S., Gilfillan S., Newberry R.D., Cella M., and Colonna M. (2013). Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781.
  24. Gao Y., Souza-Fonseca-Guimaraes F., Bald T., Ng S.S., Young A., Ngiow S.F., Rautela J., Straube J., Waddell N., and Blake S.J., et al. (2017). Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat. Immunol. 18, 1004-1015.
    Pubmed CrossRef
  25. Gascoyne D.M., Long E., Veiga-Fernandes H., de Boer J., Williams O., Seddon B., Coles M., Kioussis D., and Brady H.J.M. (2009). The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat. Immunol. 10, 1118-1124.
    Pubmed CrossRef
  26. Gasteiger G., Fan X., Dikiy S., Lee S.Y., and Rudensky A.Y. (2015). Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981-985.
    Pubmed KoreaMed CrossRef
  27. Geiger T.L., Abt M.C., Gasteiger G., Firth M.A., O'Connor M.H., Geary C.D., O'Sullivan T.E., van den Brink M.R., Pamer E.G., and Hanash A.M., et al. (2014). Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J. Exp. Med. 211, 1723-1731.
    Pubmed KoreaMed CrossRef
  28. Golebski K., Layhadi J.A., Sahiner U., Steveling-Klein E.H., Lenormand M.M., Li R.C.Y., Bal S.M., Heesters B.A., Vilà-Nadal G., and Hunewald O., et al. (2021). Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity 54, 291-307.e7.
    Pubmed CrossRef
  29. Gross C.C., Schulte-Mecklenbeck A., Hanning U., Posevitz-Fejfar A., Korsukewitz C., Schwab N., Meuth S.G., Wiendl H., and Klotz L. (2017). Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Mult. Scler. 23, 1025-1030.
    Pubmed CrossRef
  30. Halim T.Y., Steer C.A., Matha L., Gold M.J., Martinez-Gonzalez I., McNagny K.M., McKenzie A.N., and Takei F. (2014). Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425-435.
    Pubmed KoreaMed CrossRef
  31. Hatfield J.K. and Brown M.A. (2015). Group 3 innate lymphoid cells accumulate and exhibit disease-induced activation in the meninges in EAE. Cell. Immunol. 297, 69-79.
    Pubmed CrossRef
  32. Hazenberg M.D., Haverkate N.J.E., van Lier Y.F., Spits H., Krabbendam L., Bemelman W.A., Buskens C.J., Blom B., and Shikhagaie M.M. (2019). Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease. Blood Adv. 3, 3650-3660.
    Pubmed KoreaMed CrossRef
  33. Ikutani M., Yanagibashi T., Ogasawara M., Tsuneyama K., Yamamoto S., Hattori Y., Kouro T., Itakura A., Nagai Y., and Takaki S., et al. (2012). Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J. Immunol. 188, 703-713.
    Pubmed CrossRef
  34. Irshad S., Flores-Borja F., Lawler K., Monypenny J., Evans R., Male V., Gordon P., Cheung A., Gazinska P., and Noor F., et al. (2017). RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers. Cancer Res. 77, 1083-1096.
    Pubmed CrossRef
  35. Kearley J., Silver J.S., Sanden C., Liu Z., Berlin A.A., White N., Mori M., Pham T.H., Ward C.K., and Criner G.J., et al. (2015). Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42, 566-579.
    Pubmed CrossRef
  36. Kim C.H., Hashimoto-Hill S., and Kim M. (2016a). Migration and tissue tropism of innate lymphoid cells. Trends Immunol. 37, 68-79.
    Pubmed KoreaMed CrossRef
  37. Kim H.Y., DeKruyff R.H., and Umetsu D.T. (2010). The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577-584.
    Pubmed KoreaMed CrossRef
  38. Kim H.Y., Lee H.J., Chang Y.J., Pichavant M., Shore S.A., Fitzgerald K.A., Iwakura Y., Israel E., Bolger K., and Faul J., et al. (2014). Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54-61.
    Pubmed KoreaMed CrossRef
  39. Kim H.Y., Umetsu D.T., and Dekruyff R.H. (2016b). Innate lymphoid cells in asthma: will they take your breath away? Eur. J. Immunol. 46, 795-806.
    Pubmed KoreaMed CrossRef
  40. Kim J., Chang Y., Bae B., Sohn K.H., Cho S.H., Chung D.H., Kang H.R., and Kim H.Y. (2019). Innate immune crosstalk in asthmatic airways: innate lymphoid cells coordinate polarization of lung macrophages. J. Allergy Clin. Immunol. 143, 1769-1782.e11.
    Pubmed CrossRef
  41. Kim M.H., Taparowsky E.J., and Kim C.H. (2015). Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut. Immunity 43, 107-119.
    Pubmed KoreaMed CrossRef
  42. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., Harrison O., and Powrie F. (2013). Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917-931.
    Pubmed KoreaMed CrossRef
  43. Klose C.S., Kiss E.A., Schwierzeck V., Ebert K., Hoyler T., d'Hargues Y., Göppert N., Croxford A.L., Waisman A., and Tanriver Y., et al. (2013). A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature 494, 261-265.
    Pubmed CrossRef
  44. Kwong B., Rua R., Gao Y., Flickinger J. Jr., Wang Y. Jr., Kruhlak M.J. Jr., Zhu J. Jr., Vivier E. Jr., McGavern D.B. Jr., and Lazarevic V. Jr. (2017). T-bet-dependent NKp46(+) innate lymphoid cells regulate the onset of TH17-induced neuroinflammation. Nat. Immunol. 18, 1117-1127.
  45. Lambrecht B.N. and Hammad H. (2015). The immunology of asthma. Nat. Immunol. 16, 45-56.
    Pubmed CrossRef
  46. Lapidot T., Dar A., and Kollet O. (2005). How do stem cells find their way home? Blood 106, 1901-1910.
    Pubmed CrossRef
  47. Lim A.I. and Di Santo J.P. (2019). ILC-poiesis: ensuring tissue ILC differentiation at the right place and time. Eur. J. Immunol. 49, 11-18.
    Pubmed CrossRef
  48. Lim A.I., Menegatti S., Bustamante J., Le Bourhis L., Allez M., Rogge L., Casanova J.L., Yssel H., and Di Santo J.P. (2016). IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213, 569-583.
    Pubmed KoreaMed CrossRef
  49. Liu T., Barrett N.A., Kanaoka Y., Yoshimoto E., Garofalo D., Cirka H., Feng C., and Boyce J.A. (2018). Type 2 cysteinyl leukotriene receptors drive IL-33-dependent type 2 immunopathology and aspirin sensitivity. J. Immunol. 200, 915-927.
    Pubmed KoreaMed CrossRef
  50. Liu T., Wu J., Zhao J., Wang J., Zhang Y., Liu L., Cao L., Liu Y., and Dong L. (2015). Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir. Med. 109, 1391-1396.
    Pubmed CrossRef
  51. Long A., Dominguez D., Qin L., Chen S., Fan J., Zhang M., Fang D., Zhang Y., Kuzel T.M., and Zhang B. (2018). Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J. Immunol. 201, 3456-3464.
    Pubmed KoreaMed CrossRef
  52. Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., Hardwigsen J., Anguiano E., Banchereau J., and Chaussabel D., et al. (2009). Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10, 75-82.
    Pubmed CrossRef
  53. Lund S.J., Portillo A., Cavagnero K., Baum R.E., Naji L.H., Badrani J.H., Mehta A., Croft M., Broide D.H., and Doherty T.A. (2017). Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation. J. Immunol. 199, 1096-1104.
    Pubmed KoreaMed CrossRef
  54. Male V., Nisoli I., Kostrzewski T., Allan D.S.J., Carlyle J.R., Lord G.M., Wack A., and Brady H.J.M. (2014). The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J. Exp. Med. 211, 635-642.
    Pubmed KoreaMed CrossRef
  55. Meininger I., Carrasco A., Rao A., Soini T., Kokkinou E., and Mjösberg J. (2020). Tissue-specific features of innate lymphoid cells. Trends Immunol. 41, 902-917.
    Pubmed CrossRef
  56. Mjösberg J. and Eidsmo L. (2014). Update on innate lymphoid cells in atopic and non-atopic inflammation in the airways and skin. Clin. Exp. Allergy 44, 1033-1043.
    Pubmed CrossRef
  57. Montaldo E., Juelke K., and Romagnani C. (2015). Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur. J. Immunol. 45, 2171-2182.
    Pubmed CrossRef
  58. Monticelli L.A., Osborne L.C., Noti M., Tran S.V., Zaiss D.M., and Artis D. (2015). IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc. Natl. Acad. Sci. U. S. A. 112, 10762-10767.
    Pubmed KoreaMed CrossRef
  59. Monticelli L.A., Sonnenberg G.F., Abt M.C., Alenghat T., Ziegler C.G.K., Doering T.A., Angelosanto J.M., Laidlaw B.J., Yang C.Y., and Sathaliyawala T., et al. (2011). Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045-1054.
    Pubmed KoreaMed CrossRef
  60. Moral J.A., Leung J., Rojas L.A., Ruan J., Zhao J., Sethna Z., Ramnarain A., Gasmi B., Gururajan M., and Redmond D., et al. (2020). ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature 579, 130-135.
    Pubmed KoreaMed CrossRef
  61. Morita H., Kubo T., Rückert B., Ravindran A., Soyka M.B., Rinaldi A.O., Sugita K., Wawrzyniak M., Wawrzyniak P., and Motomura K., et al. (2019). Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J. Allergy Clin. Immunol. 143, 2190-2201.e9.
    Pubmed CrossRef
  62. Morita H., Moro K., and Koyasu S. (2016). Innate lymphoid cells in allergic and nonallergic inflammation. J. Allergy Clin. Immunol. 138, 1253-1264.
    Pubmed CrossRef
  63. Moro K., Kabata H., Tanabe M., Koga S., Takeno N., Mochizuki M., Fukunaga K., Asano K., Betsuyaku T., and Koyasu S. (2016). Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17, 76-86.
    Pubmed CrossRef
  64. Ni L. and Dong C. (2018). Roles of myeloid and lymphoid cells in the pathogenesis of chronic obstructive pulmonary disease. Front. Immunol. 9, 1431.
    Pubmed KoreaMed CrossRef
  65. O'Sullivan T.E. (2019). Dazed and confused: NK cells. Front. Immunol. 10, 2235.
    Pubmed KoreaMed CrossRef
  66. Panda S.K. and Colonna M. (2019). Innate lymphoid cells in mucosal immunity. Front. Immunol. 10, 861.
    Pubmed KoreaMed CrossRef
  67. Park S.M., Do-Thi V.A., Lee J.O., Lee H., and Kim Y.S. (2020). Interleukin-9 inhibits lung metastasis of melanoma through stimulating anti-tumor M1 macrophages. Mol. Cells 43, 479-490.
    Pubmed KoreaMed CrossRef
  68. Patman G. (2015). Immunology: gut migration of innate lymphoid cells. Nat. Rev. Gastroenterol. Hepatol. 12, 430.
    Pubmed CrossRef
  69. Perry J.S., Han S., Xu Q., Herman M.L., Kennedy L.B., Csako G., and Bielekova B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 4, 145ra106.
    Pubmed KoreaMed CrossRef
  70. Peters C.P., Mjosberg J.M., Bernink J.H., and Spits H. (2016). Innate lymphoid cells in inflammatory bowel diseases. Immunol. Lett. 172, 124-131.
    Pubmed CrossRef
  71. Possot C., Schmutz S., Chea S., Boucontet L., Louise A., Cumano A., and Golub R. (2011). Notch signaling is necessary for adult, but not fetal, development of RORgammat(+) innate lymphoid cells. Nat. Immunol. 12, 949-958.
  72. Rabe K.F. and Watz H. (2017). Chronic obstructive pulmonary disease. Lancet 389, 1931-1940.
    Pubmed CrossRef
  73. Reich D.S., Lucchinetti C.F., and Calabresi P.A. (2018). Multiple sclerosis. N. Engl. J. Med. 378, 169-180.
    Pubmed KoreaMed CrossRef
  74. Salimi M., Stoger L., Liu W., Go S., Pavord I., Klenerman P., Ogg G., and Xue L. (2017). Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J. Allergy Clin. Immunol. 140, 1090-1100.e11.
    Pubmed KoreaMed CrossRef
  75. Saranchova I., Han J., Zaman R., Arora H., Huang H., Fenninger F., Choi K.B., Munro L., Pfeifer C.G., and Welch I., et al. (2018). Type 2 innate lymphocytes actuate immunity against tumours and limit cancer metastasis. Sci. Rep. 8, 2924.
    Pubmed KoreaMed CrossRef
  76. Scandella E., Bolinger B., Lattmann E., Miller S., Favre S., Littman D.R., Finke D., Luther S.A., Junt T., and Ludewig B. (2008). Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9, 667-675.
    Pubmed CrossRef
  77. Scanlon S.T. and McKenzie A.N. (2012). Type 2 innate lymphoid cells: new players in asthma and allergy. Curr. Opin. Immunol. 24, 707-712.
    Pubmed CrossRef
  78. Serafini N., Klein Wolterink R.G., Satoh-Takayama N., Xu W., Vosshenrich C.A., Hendriks R.W., and Di Santo J.P. (2014). Gata3 drives development of RORgammat+ group 3 innate lymphoid cells. J. Exp. Med. 211, 199-208.
  79. Silver J.S., Kearley J., Copenhaver A.M., Sanden C., Mori M., Yu L., Pritchard G.H., Berlin A.A., Hunter C.A., and Bowler R., et al. (2016). Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat. Immunol. 17, 626-635.
    Pubmed KoreaMed CrossRef
  80. Smith S.G., Chen R., Kjarsgaard M., Huang C., Oliveria J.P., O'Byrne P.M., Gauvreau G.M., Boulet L.P., Lemiere C., and Martin J., et al. (2016). Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137, 75-86.e8.
    Pubmed CrossRef
  81. Spits H. and Cupedo T. (2012). Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647-675.
    Pubmed CrossRef
  82. Suzuki M., Sze M.A., Campbell J.D., Brothers J.F., Lenburg M.E., McDonough J.E., Elliott W.M., Cooper J.D., Spira A., and Hogg J.C. (2017). The cellular and molecular determinants of emphysematous destruction in COPD. Sci. Rep. 7, 9562.
    Pubmed KoreaMed CrossRef
  83. Tanriver Y. and Diefenbach A. (2014). Transcription factors controlling development and function of innate lymphoid cells. Int. Immunol. 26, 119-128.
    Pubmed CrossRef
  84. Trabanelli S., Chevalier M.F., Martinez-Usatorre A., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., and Papayannidis C., et al. (2017). Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat. Commun. 8, 593.
    Pubmed KoreaMed CrossRef
  85. van de Pavert S.A., Olivier B.J., Goverse G., Vondenhoff M.F., Greuter M., Beke P., Kusser K., Höpken U.E., Lipp M., and Niederreither K., et al. (2009). Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat. Immunol. 10, 1193-1199.
    Pubmed KoreaMed CrossRef
  86. Vivier E., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., Koyasu S., Locksley R.M., McKenzie A.N.J., and Mebius R.E., et al. (2018). Innate lymphoid cells: 10 years on. Cell 174, 1054-1066.
    Pubmed CrossRef
  87. Walker J.A., Clark P.A., Crisp A., Barlow J.L., Szeto A., Ferreira A.C.F., Rana B.M.J., Jolin H.E., Rodriguez-Rodriguez N., and Sivasubramaniam M., et al. (2019). Polychromic reporter mice reveal unappreciated innate lymphoid cell progenitor heterogeneity and elusive ILC3 progenitors in bone marrow. Immunity 51, 104-118.e7.
    Pubmed KoreaMed CrossRef
  88. Wan J., Wu Y., Huang L., Tian Y., Ji X., Abdelaziz M.H., Cai W., Dineshkumar K., Lei Y., and Yao S., et al. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett. 502, 34-43.
    Pubmed CrossRef
  89. Wang S., Xia P., Chen Y., Qu Y., Xiong Z., Ye B., Du Y., Tian Y., Yin Z., and Xu Z., et al. (2017). Regulatory innate lymphoid cells control innate intestinal inflammation. Cell 171, 201-216.e18.
    Pubmed CrossRef
  90. Wills-Karp M. and Finkelman F.D. (2011). Innate lymphoid cells wield a double-edged sword: type 2 cytokine-producing innate lymphoid cells are present in human and mouse lungs, where they contribute to both type 2 immune responses and tissue repair. Nat. Immunol. 12, 1025-1028.
  91. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., and Sabat R. (2004). IL-22 increases the innate immunity of tissues. Immunity 21, 241-254.
    Pubmed CrossRef
  92. Wolterink R.G., KleinJan A., van Nimwegen M., Bergen I., de Bruijn M., Levani Y., and Hendriks R.W. (2012). Pulmonary innate lymphoid cells are major producers of IL‐5 and IL‐13 in murine models of allergic asthma. Eur. J. Immunol. 42, 1106-1116.
  93. Xu W., Domingues R.G., Fonseca-Pereira D., Ferreira M., Ribeiro H., Lopez-Lastra S., Motomura Y., Moreira-Santos L., Bihl F., and Braud V., et al. (2015). NFIL3 orchestrates the emergence of common helper innate lymphoid cell precursors. Cell Rep. 10, 2043-2054.
    Pubmed CrossRef
  94. Yagi R., Zhong C., Northrup D.L., Yu F., Bouladoux N., Spencer S., Hu G., Barron L., Sharma S., and Nakayama T., et al. (2014). The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity 40, 378-388.
  95. Zeng B., Shi S., Ashworth G., Dong C., Liu J., and Xing F. (2019). ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis. 10, 315.
    Pubmed KoreaMed CrossRef
  96. Zlotoff D.A., Sambandam A., Logan T.D., Bell J.J., Schwarz B.A., and Bhandoola A. (2010). CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus. Blood 115, 1897-1905.
    Pubmed KoreaMed CrossRef
  97. Zook E.C. and Kee B.L. (2016). Development of innate lymphoid cells. Nat. Immunol. 17, 775-782.
    Pubmed CrossRef

Article

Minireview

Mol. Cells 2021; 44(5): 301-309

Published online May 31, 2021 https://doi.org/10.14348/molcells.2021.0053

Copyright © The Korean Society for Molecular and Cellular Biology.

Innate Lymphoid Cells in Tissue Homeostasis and Disease Pathogenesis

Jihyun Kim1,2 , Seungwon Ryu1 , and Hye Young Kim1,2, *

1Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea, 2Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul 03080, Korea

Correspondence to:hykim11@snu.ac.kr

Received: March 6, 2021; Revised: March 30, 2021; Accepted: March 30, 2021

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/.

Abstract

Innate lymphoid cells (ILCs) are the most recently discovered family of innate immune cells. ILCs can be categorized into three groups on the basis of the transcription factors that direct their functions and the cytokines they produce. Notably, these functions parallel the effector functions of T lymphocytes. ILCs play a frontline role in host defense and tissue homeostasis by responding rapidly to environmental factors, conducting effector responses in a tissue-specific manner, and interacting with hematopoietic and non-hematopoietic cells throughout the body. Moreover, recent studies reveal that ILCs are involved in development of various inflammatory diseases, such as respiratory diseases, autoimmune diseases, or cancer. In this review, we discuss the recent findings regarding the biology of ILCs in health and inflammatory diseases.

Keywords: development, homeostasis, inflammation, innate lymphoid cells, plasticity, tropism

INTRODUCTION

Innate lymphoid cells (ILCs) are recently identified lymphocytes that lack antigen-specific receptors but have similar functions as T cells and thus serve as the innate counterparts to T cells (Diefenbach et al., 2014; Spits and Cupedo, 2012). They respond quickly to signals from the tissue environment and are in general enriched in barrier tissues (i.e., skin, lung, and intestine) rather than in lymphoid tissues. There are three ILC subsets, each of which displays a distinct predilection for particular tissues. Within these tissues, the ILCs play specific roles in homeostasis and disease (Mjösberg and Eidsmo, 2014; Patman, 2015) that will be discussed in this review.

INNATE LYMPHOID CELLS

ILC subsets

Unlike lineage cells such as T cells, B cells, and myeloid cells, ILCs do not express lineage markers (Vivier et al., 2018). Instead, they can be divided into three groups (group 1 ILCs, group 2 ILCs, and group 3 ILCs) on the basis of the cytokines they produce and the master regulatory transcription factors that drive their development and functions.

Group 1 ILCs include ILC1s and natural killer cells (NK cells). They express CD161 and interleukin (IL)-12 receptor beta (IL-12Rβ) on their surface, and their master transcription factor is T-bet (Cortez and Colonna, 2016; O'Sullivan, 2019). ILC1s are the innate counterpart to Th1 cells since they secrete interferon γ (IFNγ) and tumor necrosis factor α (TNFα), while NK cells are considered to be the innate counterpart to type 1 cytotoxic T (Tc1) cells since they produce TNFα, IFNγ, perforin, and granzyme.

Group 2 ILCs (ILC2s) express the IL-33 receptor (IL-33R) and the transcription factors GATA binding protein 3 (GATA3) and RAR-related orphan receptor alpha (RORα) (Entwistle et al., 2020). ILC2s are the counterparts to Th2 cells because they produce large amounts of type 2 cytokines such as IL-5 and IL-13. ILC2s also express other cytokines, including amphiregulin, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-9 (Morita et al., 2016).

Group 3 ILCs are subdivided into three populations according to their expression of C-C motif chemokine receptor 6 (CCR6) and natural cytotoxicity receptors (NCR) (i.e., NKp46 in mice and NKp44 in humans). Thus, the CCR6+ cells are designated LTi; these cells produce lymphotoxins (LT). The CCR6- cells are divided further into NCR+ ILC3s and NCR- ILC3s (Montaldo et al., 2015). ILC3s typically express IL-1 and IL-23 receptors and the RORγt and aryl-hydrocarbon receptor (AhR) transcription factors (Meininger et al., 2020).

Recently, several groups identified a new subset of ILCs, namely, IL-10-producing regulatory ILCs (ILCregs) (Golebski et al., 2021; Morita et al., 2019; Wang et al., 2017). Wang et al. showed that they express a distinct transcription factor, namely, ID3 (inhibitor of DNA binding 3), and that autocrine transforming growth factor beta (TGF-β) signaling is important for their development (Wang et al., 2017). However, other groups have also reported that ILCregs can be derived from ILC2s by retinoic acid (RA) (Golebski et al., 2021; Morita et al., 2019). Further studies on the origin and functions of ILCregs are required.

Development and differentiation of ILCs

ILCs develop from common lymphoid progenitors (CLPs) in the fetal liver and the adult bone marrow (Zook and Kee, 2016). In the mouse, the differentiation of CLPs into mature ILC subsets is regulated by the coordinated expression of a variety of transcription factors that activate or repress critical target genes. These transcription factors include ID2, NFIL3, promyelocytic leukemia zinc finger (PLZF) (encoded by Zbtb16), TCF1 (encoded by Tcf7), and GATA3 (Eberl et al., 2015; Vivier et al., 2018) (Fig. 1). NFIL3 plays a particularly important role since it controls ID2, GATA3, EOMES, and T-bet and thereby orchestrates ILC differentiation (Gascoyne et al., 2009; Male et al., 2014; Xu et al., 2015). The transcriptional ILC differentiation program starts with CLPs expressing NFIL3 and TCF1; this causes them to differentiate into early innate lymphoid progenitors (EILPs), which are the lineage-committed cells for ILCs and NK cells (Geiger et al., 2014; Tanriver and Diefenbach, 2014). The EILPs then differentiate into common helper ILC precursors (CHILPs) due to ID2 and GATA3 expression (Serafini et al., 2014; Tanriver and Diefenbach, 2014; Yagi et al., 2014). Subsequently, PLZF expression drives the development of ILC precursors (ILCp) from CHILPs (Constantinides et al., 2014; 2015). The ILCp exits the fetal liver or adult bone marrow and then circulate in the blood (Eberl et al., 2015). There is also evidence that some ILCp matures in the bone marrow before entering the bloodstream (Eberl et al., 2015; Walker et al., 2019).

Tissue tropism of ILCs

A growing body of evidence suggests that ILC subsets are strategically localized in specific tissues in a way that relates to their roles in immune responses (Bando et al., 2015; Kim et al., 2016a). Thus, ILC1s are largely located in the intraepithelium of the intestine (Fuchs et al., 2013); ILC2s predominate in the lung, skin, and white adipose tissue; and ILC3s are a major population in the lamina propria, cryptopatches, and Peyer’s patches of the intestinal tract (Klose et al., 2013; Luci et al., 2009). This tissue tropism is determined in part by the tissues, which present a signature array of adhesion molecules and emit chemokines, and in part by the ILCp and mature ILCs, which express characteristic homing receptors, including integrins and chemoattractant receptors, that cause them to migrate from the circulation into the peripheral tissues (Lapidot et al., 2005). For example, ILCp expresses integrin α4β7 (Constantinides et al., 2014; Possot et al., 2011) while endothelial cells express the binding partners of α4β7, namely, mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and vascular cell adhesion protein 1 (VCAM-1) at high levels (Deem and Cook-Mills, 2004; Erle et al., 1994). The encounter between ILCp and MAdCAM-1- and VCAM-1-positive endothelium causes the ILCp to stick and then extravasate into the tissue. Thus, α4β7 guides ILCp to mucosal and non-mucosal tissues. Similarly, the ILCp expresses chemokine receptors that guide their migration towards the corresponding chemokines emitted by the tissues. These chemokine receptors include C-X-C motif chemokine receptor 6 (CXCR6), which seems to play an important role in the emigration of ILCp from the bone marrow and their peripheral seeding, and CCR7 and CCR9, which are key gut-homing receptors on ILCs (Chea et al., 2015; Kim et al., 2015; Patman, 2015; Possot et al., 2011; Zlotoff et al., 2010). Thus, by expressing specific homing receptors, ILCp and mature ILCs migrate to specific peripheral tissues (Fig. 2).

ILC plasticity

Once ILCp and mature ILCs enter the tissues, they seem to reside there and proliferate locally. A parabiosis mouse model showed that under homeostatic conditions, ILCs reside in the tissue whereas other lymphocytes circulate through the bloodstream (Gasteiger et al., 2015; Kim et al., 2016a; Moro et al., 2016). In the tissue, ILCp matures into ILC subsets that appear to be shaped by microenvironmental cues (Lim and Di Santo, 2019).

While mature ILCs has less differentiation capacity than ILCp, it is clear that the ILC subtype phenotypes are plastic, meaning they can convert into other subtypes in response to environmental cytokines (Fig. 3). For example, a study that used the genetic fate mapping technique to mark cells showed that stimulating RORγt+ ILC3s with IL-12 and IL-15 increased their expression of T-bet and IFNγ, which is characteristic of ILC1s; this treatment also decreased their expression of RORγt (Bernink et al., 2015; Montaldo et al., 2015). The converse effect is also true: ILC1s can be changed both in vivo and in vitro into ILC3s by IL-2, IL-1β, and IL-23 (Bernink et al., 2015). There is a similar reversible axis of plasticity between ILC2s and ILC1s: ILC2s stimulated in vitro with IL-12 exhibit increased expression of T-bet and IFNγ, and this is reversed by IL-4 (Bal et al., 2016; Lim et al., 2016; Silver et al., 2016). This ILC plasticity highlights the consummate ability of ILCs to sense, communicate with, and adapt to the surrounding microenvironment. As we will see below, these activities of ILCs participate both in tissue homeostasis and inflammation.

ROLES OF ILCS IN TISSUE HOMEOSTASIS

ILCs help remodel injured tissue in a variety of ways, thereby maintaining tissue integrity. For example, by inducing stromal lymphoid tissue organizer cells to produce chemokines (i.e., C-X-C motif chemokine ligand 13 [CXCL13], CCL21, and CCL19) and adhesion molecules (VCAM-1, MAdCAM-1, and intercellular adhesion molecule 1 [ICAM-1]), the ILC3 subset LTi promotes the formation of secondary lymphoid organs such as Peyer’s patches in the gut, which play an important role in gut homeostasis in the face of microbial colonization and food-derived antigens (van de Pavert et al., 2009). ILC3s also restore secondary lymphoid organs after they have been destroyed by a viral infection (Scandella et al., 2008). Moreover, ILC3s help rehabilitate intestinal epithelium that has been damaged (for example by chemotherapy) by secreting IL-22 (Hazenberg et al., 2019): this induces IL-22 receptor-expressing intestinal stem cells to regenerate the epithelial cells (Wolk et al., 2004). In addition, the intestinal epithelial lesions in dextran sodium sulfate (DSS)-induced colitis can be repaired by ILC2s that have been stimulated with the epithelial cytokine IL-33: these cells produce amphiregulin, which binds to epidermal growth factor receptor (EGFR) on epithelial cells and thereby regulates their differentiation and proliferation (Monticelli et al., 2015). These effects of amphiregulin-expressing ILC2s are also critical for restoring airway epithelial integrity and tissue homeostasis after influenza virus infection (Monticelli et al., 2011). These observations suggest that therapeutically targeting homeostatic ILC responses in tissues could help manage tissue damage.

ILCS IN INFLAMMATORY DISEASES

The local tissue microenvironment in inflamed tissues can be very different from that in healthy non-inflamed tissues. This can cause ILCs to change their phenotype and functions in both beneficial and pathogenic ways. We discuss below how ILCs act in several inflammatory diseases, namely, asthma, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), and cancer (Fig. 1). It should be noted that despite the essential roles of ILCs in gut homeostasis and tissue repair (see above), these cells also contribute to inflammatory bowel diseases (IBD) and several infectious diseases. For detailed information on ILCs in IBD and infectious diseases, we recommend related excellent reviews (Panda and Colonna, 2019; Peters et al., 2016; Zeng et al., 2019).

Asthma

Asthma is a chronic inflammatory disease that affects about 300 million people worldwide (Beasley and Hancox, 2020). It is characterized by difficulty breathing, coughing, and wheezing that is caused by airway hyperresponseveness (AHR), mucus overproduction, and airway remodeling (Lambrecht and Hammad, 2015). Multiple studies show that ILCs may play key roles in asthma pathogenesis (Kim et al., 2016b; Scanlon and McKenzie, 2012). This was first discovered when allergic asthma models and patients were found to have pulmonary ILC2s that produce large amounts of type 2 cytokines; these cytokines have long been noted to play key pathogenic roles in this classical asthma endotype (Kim et al., 2016b). It is now thought that the pathogenic role of pulmonary ILC2s starts when these cells are activated by various factors that are promptly upregulated in the lungs by allergens: they include the epithelial cytokines IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) and the mast cell factors cysteinyl leukotrienes and prostaglandins (Doherty and Broide, 2019; Liu et al., 2018; Lund et al., 2017; Salimi et al., 2017). The activated ILC2s then recruit other immune cells, including eosinophils and alternatively activated (M2) macrophages; these cells induce AHR and airway inflammation (Halim et al., 2014; Wolterink et al., 2012).

Notably, ILC2s participate in influenza virus-induced asthma in both a pathogenic and a beneficial way. Thus, the virus-damaged epithelial cells secrete IL-33, which stimulates ILC2s and thereby worsens airway inflammation (Chang et al., 2011). On the other hand, the influenza infection stimulates ILC2s to secrete amphiregulin, which causes the damaged epithelial cells to regenerate (Monticelli et al., 2011; Wills-Karp and Finkelman, 2011). ILC2s also play a well-recognized role in the pathology of eosinophilic asthma in humans: patients with severe asthma have increased numbers of ILC2s in their blood and sputum and the disease severity correlates with the amount of type 2 cytokines produced by ILC2s but not the Th2 cells (Liu et al., 2015; Smith et al., 2016). We also found that ILC2s induce the polarization of M2 macrophages in patients with eosinophilic asthma (Kim et al., 2019).

Interestingly, the latter study also showed that in non-eosinophilic asthma, ILC1s and ILC3s, but not ILC2s, activate classically activated (M1) macrophages (Kim et al., 2019). Thus, different types of ILCs may be responsible for the asthma phenotypes in humans. This is supported by studies showing that ILC3s may participate in the non-allergic asthma endotypes that appear to arise independently of Th2 cells (Everaere et al., 2016; Kim et al., 2014); these endotypes include those driven by obesity or environmental factors such as ozone, diesel particles, and cold air (Kim et al., 2010). For example, we observed that when mice were fed a high-fat diet, they spontaneously developed AHR and had significant lung numbers of CCR6+ ILC3s that produced IL-17A, which is a potent neutrophil chemotactic agent. We then showed that these ILC3s were activated and induced to proliferate by IL-1β from M1 macrophages (Kim et al., 2014).

These observations together demonstrate the crucial importance of ILCs in asthma. Further intensive exploration of ILCs is needed since targeting these immune axes could be of therapeutic value.

Chronic obstructive pulmonary disease

COPD includes pulmonary emphysema and chronic bronchitis and is a progressive respiratory disease characterized by long-term breathing problems and obstructed airflow (Rabe and Watz, 2017). The most common risk factor for COPD is smoking. The signature immune responses in this disease are activated neutrophils, macrophages, Th1 cells, Th17 cells, and CD8+ T cells (Bhat et al., 2015; Ni and Dong, 2018).

Although there are fewer studies on COPD than on asthma, several reports suggest that ILCs are also involved in COPD pathogenesis. Kearley et al. showed that chronic exposure to cigarette smoke exacerbates virus-induced lung inflammation and that this associates with a shift away from ILC2 responses to proinflammatory macrophage and NK cell responses using a murine model of virus-induced COPD. Specifically, smoke exposure increases IL-33 secretion from epithelial cells while simultaneously decreasing and increasing IL-33R expression on ILC2s and macrophages/NK cells, respectively (Kearley et al., 2015). Notably, Silver et al. showed that (inflammatory triggers of COPD also provoke pathogenic ILC subset plasticity. They first showed that viral infection and long-term smoking convert ILC2s into ILC1-like populations that express IL-12Rβ2, IL-18 receptor alpha (IL-18Rα), T-bet, and IFNγ. Subsequently, they showed that the severity of COPD correlates with increased ILC1s and decreased ILC2s in the peripheral blood (Silver et al., 2016). The role of ILC3s in COPD is less well studied than the ILC1s and ILC2s, but it has been shown that COPD patients have higher ILC3 frequencies in lung biopsies than control subjects (De Grove et al., 2016). Moreover, COPD lungs, but not unused donor lungs, abundantly express the gene set that relates to the ILC3 subset LTi (Suzuki et al., 2017). Therefore, further studies on the relevance of ILCs, including the ILC3s, in COPD pathogenesis are warranted.

Multiple sclerosis

MS is the most common inflammatory demyelinating disease of the central nervous system (CNS) (Reich et al., 2018). Clinical presentation of MS depends on the location of the demyelinating lesions, leading to its heterogeneous characteristics. It includes sensory or motor symptoms, fatigue, pain, and cognitive decline (Filippi et al., 2018). Since MS is regarded to be a Th17 cell-mediated disease, most of the research on ILCs in MS has focused on the ILC3 subsets. Accordingly, it has been shown that compared to control subjects, patients with MS have higher numbers of ILC3s, including LTi cells, in their cerebrospinal fluid and blood (Degn et al., 2016; Gross et al., 2017). However, when MS patients were treated with Daclizumab, which blocked IL-2 receptor alpha and previously used to treat relapsing MS, their circulating ILC3s (LTi cells) dropped, but NK cells rose. Notably, significant treatment effects were not observed on the frequencies of activated T cells (Perry et al., 2012). These findings suggest that ILC3s contribute to MS pathogenesis. This is supported by studies in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. Hatfield and Browns showed that ILC3s are normal resident cells in the meninges (which are where the immune cell infiltration to the CNS starts) and that in EAE, these cells overexpress IFNγ, IL-17, and GM-CSF. This suggests that ILC3s could contribute at an early stage to EAE pathogenesis (Hatfield and Brown, 2015). Moreover, Kwong et al. showed that when encephalitogenic T cells are transferred to T-bet depleted mice, the infiltration of T cells into the CNS is lower than in wildtype mice. It was then shown that the specific loss of T-bet expression in NKp46+ T-bet+ ILCs (i.e., ILC1s or the NKp46+ subset of ILC3s) impairs the ability of the encephalitogenic T cells to invade the CNS (Kwong et al., 2017). These results suggest that despite the fact that ILCs are a minor population in the CNS, they can control the initiation of inflammation in EAE.

Cancer

While cancer is a complex disease, studies in recent years have started to elucidate the roles of ILCs in tumor development. The study of Dadi et al. showed that ILC1s can have anti-tumor effects: when breast cancer arises spontaneously in mice, the mammary glands contain elevated frequencies of ILC1s that bear NK cell characteristics (IFNγ and granzyme B production) and are cytotoxic to tumor cells (Dadi et al., 2016). By contrast, a study with MCA1956 carcinogen-induced sarcoma shows that by expressing TGF-β, tumors can escape NK cell-mediated tumor control by converting cytotoxic NK cells into ILC1s, which are unable to control tumor growth and metastasis (Gao et al., 2017).

The roles of ILC2s in cancer immune response are also controversial. Rag-/- mice challenged with IL-33-expressing B16-melanoma cells develop tumors less effectively than mice challenged with wildtype tumor cells: this is due to the IL-33-mediated expansion and activation of cytotoxic NK cells. However, this beneficial effect of IL-33 is tempered by its effect on ILC2s, which inhibit NK cell activation and cytotoxicity via immunosuppressive enzyme CD73 (Long et al., 2018). Similarly, ILC2s produce IL-13 in the acute promyelocytic leukemia animal model, which activates monocytic myeloid-derived suppressor cells (M-MDSCs) thereby enhances tumor progression (Trabanelli et al., 2017). However, several other studies observe that ILC2s can also have anti-tumor effects. Thus, genetic deletion of ILC2s in mice associates with increased tumor growth and metastasis (Saranchova et al., 2018). Moreover, in pancreatic ductal adenocarcinoma, intratumoral ILC2s activate CD103+ dendritic cells and enhance the anti-tumor responses of CD8+ T cells (Moral et al., 2020). In addition, in a lung metastatic melanoma model, ILC2s produce IL-5, thereby activating eosinophils and increasing their anti-tumor response (Ikutani et al., 2012). Moreover, ILC2s produce IL-9, which is important to suppress metastasis of cancer cells, in tumor microenvironment (Park et al., 2020; Wan et al., 2021).

Similarly, divergent roles were observed for ILC3s. For examples, in models of preclinical breast cancer and invasive colon cancer, ILC3s promote tumor growth and metastasis by producing IL-22 (Irshad et al., 2017; Kirchberger et al., 2013). By contrast, in the B16 melanoma model, NKp46+ ILC3s increase leukocyte invasion and tumor suppression by producing IL-12 and upregulating ICAM-1 and VCAM-1 (Eisenring et al., 2010).

Although studies over the last few years have provided critical insights into the role of ILCs in anti-tumor immune responses, many aspects remain to be explored.

CONCLUSION

Since ILCs adapt remarkably quickly and fluidly to environmental cues and orchestrate downstream immunity, including adaptive immune responses, they are fundamental front-line defenders of the host. However, because of their sparsity relative to other immune cells, the importance of ILCs has long been underestimated. Since ILCs share many properties with T cells, specific treatment targeting ILCs is not available until now. However, the present review clearly shows that ILCs participate in both tissue homeostasis and disease pathogenesis, thus could be potential therapeutic targets for managing diseases. ILCs might play an important role in priming the immune response at the various stages of the disease by secreting large amounts of cytokines prior to T cells by rapidly responding to alarmins. Therefore, targeting alarmins could be one of the promising approaches to regulating ILCs for disease control, although further experiments are required.

ACKNOWLEDGMENTS

This study was supported by a grant from the National Research Foundation of Korea (NRF-2019R1A2C2087574) and a grant from the MD-PhD/Medical Scientist Training Program through the Korea Health Industry Development Institute (KHIDI), which was funded by the Ministry of Health & Welfare, Republic of Korea.

AUTHOR CONTRIBUTIONS

J.K., S.R., and H.Y.K. wrote and revised the manuscript.

CONFLICT OF INTEREST

The authors have no potential conflicts of interest to disclose.

Fig 1.

Download
Figure 1.Development and function of ILCs. ILC differentiation proceeds in a stepwise fashion from hematopoietic stem cells (HSCs) to lymphoid lineage restricted precursors. The development of ILCs from CLPs requires ID2-mediated suppression of alternative lymphoid cell fates that generate B and T cells. CLPs further commit to the ILC/NK lineage via multi‐potent ILCp. Individual subsets depend on the expression of specific transcription factors that determine their terminal differentiation and function. CLP, common lymphoid progenitor; EILP, early innate lymphoid progenitor; CHILP, common helper ILC precursor; NKp, NK cell precursor; ILCp, ILC precursor; LTip, LTi cell precursor.
Molecules and Cells 2021; 44: 301-309https://doi.org/10.14348/molcells.2021.0053

Fig 2.

Download
Figure 2.Tissue tropism of ILCs. ILCp derived from bone marrow hematopoiesis enters the blood to home to lymphoid and non-lymphoid organs. This process requires the expression of various chemokine receptors and α4β7 integrin. Their strategic position within tissues allows ILCs to act as a monitor of healthy tissue and to enable a rapid response to inflammatory signals. CLP, common lymphoid progenitor; ILCp, ILC precursor.
Molecules and Cells 2021; 44: 301-309https://doi.org/10.14348/molcells.2021.0053

Fig 3.

Download
Figure 3.Plasticity of ILCs. ILCs exhibit plasticity that can switch between fully polarized subsets to quickly adapt to changes occurring in the environment. The plasticity of ILC1, ILC2, and ILC3 depends on signals from the tissue microenvironment, mainly the cytokine milieu.
Molecules and Cells 2021; 44: 301-309https://doi.org/10.14348/molcells.2021.0053

References

  1. Bal S.M., Bernink J.H., Nagasawa M., Groot J., Shikhagaie M.M., Golebski K., van Drunen C.M., Lutter R., Jonkers R.E., and Hombrink P., et al. (2016). IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat. Immunol. 17, 636-645.
  2. Bando J.K., Liang H.E., and Locksley R.M. (2015). Identification and distribution of developing innate lymphoid cells in the fetal mouse intestine. Nat. Immunol. 16, 153-160.
    Pubmed KoreaMed CrossRef
  3. Beasley R. and Hancox R.J. (2020). Reducing the burden of asthma: time to set research and clinical priorities. Lancet Respir. Med. 8, 943-944.
    Pubmed CrossRef
  4. Bernink J.H., Krabbendam L., Germar K., de Jong E., Gronke K., Kofoed-Nielsen M., Munneke J.M., Hazenberg M.D., Villaudy J., and Buskens C.J. (2015). Interleukin-12 and-23 control plasticity of CD127+ group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity 43, 146-160.
    Pubmed CrossRef
  5. Bhat T.A., Panzica L., Kalathil S.G., and Thanavala Y. (2015). Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 12(Suppl 2), S169-S175.
    Pubmed KoreaMed CrossRef
  6. Chang Y.J., Kim H.Y., Albacker L.A., Baumgarth N., McKenzie A.N., Smith D.E., Dekruyff R.H., and Umetsu D.T. (2011). Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat. Immunol. 12, 631-638.
    Pubmed KoreaMed CrossRef
  7. Chea S., Possot C., Perchet T., Petit M., Cumano A., and Golub R. (2015). CXCR6 expression is important for retention and circulation of ILC precursors. Mediators Inflamm. 2015, 368427.
    Pubmed KoreaMed CrossRef
  8. Constantinides M.G., Gudjonson H., McDonald B.D., Ishizuka I.E., Verhoef P.A., Dinner A.R., and Bendelac A. (2015). PLZF expression maps the early stages of ILC1 lineage development. Proc. Natl. Acad. Sci. U. S. A. 112, 5123-5128.
    Pubmed KoreaMed CrossRef
  9. Constantinides M.G., McDonald B.D., Verhoef P.A., and Bendelac A. (2014). A committed precursor to innate lymphoid cells. Nature 508, 397-401.
    Pubmed KoreaMed CrossRef
  10. Cortez V.S. and Colonna M. (2016). Diversity and function of group 1 innate lymphoid cells. Immunol. Lett. 179, 19-24.
    Pubmed KoreaMed CrossRef
  11. Dadi S., Chhangawala S., Whitlock B.M., Franklin R.A., Luo C.T., Oh S.A., Toure A., Pritykin Y., Huse M., and Leslie C.S., et al. (2016). Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365-377.
    Pubmed KoreaMed CrossRef
  12. De Grove K.C., Provoost S., Verhamme F.M., Bracke K.R., Joos G.F., Maes T., and Brusselle G.G. (2016). Characterization and quantification of innate lymphoid cell subsets in human lung. PLoS One 11, e0145961.
    Pubmed KoreaMed CrossRef
  13. Deem T.L. and Cook-Mills J.M. (2004). Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 104, 2385-2393.
    Pubmed KoreaMed CrossRef
  14. Degn M., Modvig S., Dyring-Andersen B., Bonefeld C.M., Frederiksen J.L., Geisler C., and von Essen M.R. (2016). Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis. Mult. Scler. 22, 1013-1020.
    Pubmed CrossRef
  15. Diefenbach A., Colonna M., and Koyasu S. (2014). Development, differentiation, and diversity of innate lymphoid cells. Immunity 41, 354-365.
    Pubmed KoreaMed CrossRef
  16. Doherty T.A. and Broide D.H. (2019). Airway innate lymphoid cells in the induction and regulation of allergy. Allergol. Int. 68, 9-16.
    Pubmed KoreaMed CrossRef
  17. Eberl G., Colonna M., Di Santo J.P., and McKenzie A.N. (2015). Innate lymphoid cells: a new paradigm in immunology. Science 348, aaa6566.
    Pubmed KoreaMed CrossRef
  18. Eisenring M., vom Berg J., Kristiansen G., Saller E., and Becher B. (2010). IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11, 1030-1038.
    Pubmed CrossRef
  19. Entwistle L.J., Gregory L.G., Oliver R.A., Branchett W.J., Puttur F., and Lloyd C.M. (2020). Pulmonary group 2 innate lymphoid cell phenotype is context specific: determining the effect of strain, location, and stimuli. Front. Immunol. 10, 3114.
    Pubmed KoreaMed CrossRef
  20. Erle D.J., Briskin M.J., Butcher E.C., Garcia-Pardo A., Lazarovits A.I., and Tidswell M. (1994). Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J. Immunol. 153, 517-528.
    Pubmed
  21. Everaere L., Ait-Yahia S., Molendi-Coste O., Vorng H., Quemener S., LeVu P., Fleury S., Bouchaert E., Fan Y., and Duez C., et al. (2016). Innate lymphoid cells contribute to allergic airway disease exacerbation by obesity. J. Allergy Clin. Immunol. 138, 1309-1318.e11.
    Pubmed CrossRef
  22. Filippi M., Bar-Or A., Piehl F., Preziosa P., Solari A., Vukusic S., and Rocca M.A. (2018). Multiple sclerosis. Nat. Rev. Dis. Primers 4, 43.
    Pubmed CrossRef
  23. Fuchs A., Vermi W., Lee J.S., Lonardi S., Gilfillan S., Newberry R.D., Cella M., and Colonna M. (2013). Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781.
  24. Gao Y., Souza-Fonseca-Guimaraes F., Bald T., Ng S.S., Young A., Ngiow S.F., Rautela J., Straube J., Waddell N., and Blake S.J., et al. (2017). Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat. Immunol. 18, 1004-1015.
    Pubmed CrossRef
  25. Gascoyne D.M., Long E., Veiga-Fernandes H., de Boer J., Williams O., Seddon B., Coles M., Kioussis D., and Brady H.J.M. (2009). The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat. Immunol. 10, 1118-1124.
    Pubmed CrossRef
  26. Gasteiger G., Fan X., Dikiy S., Lee S.Y., and Rudensky A.Y. (2015). Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981-985.
    Pubmed KoreaMed CrossRef
  27. Geiger T.L., Abt M.C., Gasteiger G., Firth M.A., O'Connor M.H., Geary C.D., O'Sullivan T.E., van den Brink M.R., Pamer E.G., and Hanash A.M., et al. (2014). Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J. Exp. Med. 211, 1723-1731.
    Pubmed KoreaMed CrossRef
  28. Golebski K., Layhadi J.A., Sahiner U., Steveling-Klein E.H., Lenormand M.M., Li R.C.Y., Bal S.M., Heesters B.A., Vilà-Nadal G., and Hunewald O., et al. (2021). Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity 54, 291-307.e7.
    Pubmed CrossRef
  29. Gross C.C., Schulte-Mecklenbeck A., Hanning U., Posevitz-Fejfar A., Korsukewitz C., Schwab N., Meuth S.G., Wiendl H., and Klotz L. (2017). Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Mult. Scler. 23, 1025-1030.
    Pubmed CrossRef
  30. Halim T.Y., Steer C.A., Matha L., Gold M.J., Martinez-Gonzalez I., McNagny K.M., McKenzie A.N., and Takei F. (2014). Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 40, 425-435.
    Pubmed KoreaMed CrossRef
  31. Hatfield J.K. and Brown M.A. (2015). Group 3 innate lymphoid cells accumulate and exhibit disease-induced activation in the meninges in EAE. Cell. Immunol. 297, 69-79.
    Pubmed CrossRef
  32. Hazenberg M.D., Haverkate N.J.E., van Lier Y.F., Spits H., Krabbendam L., Bemelman W.A., Buskens C.J., Blom B., and Shikhagaie M.M. (2019). Human ectoenzyme-expressing ILC3: immunosuppressive innate cells that are depleted in graft-versus-host disease. Blood Adv. 3, 3650-3660.
    Pubmed KoreaMed CrossRef
  33. Ikutani M., Yanagibashi T., Ogasawara M., Tsuneyama K., Yamamoto S., Hattori Y., Kouro T., Itakura A., Nagai Y., and Takaki S., et al. (2012). Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J. Immunol. 188, 703-713.
    Pubmed CrossRef
  34. Irshad S., Flores-Borja F., Lawler K., Monypenny J., Evans R., Male V., Gordon P., Cheung A., Gazinska P., and Noor F., et al. (2017). RORγt+ innate lymphoid cells promote lymph node metastasis of breast cancers. Cancer Res. 77, 1083-1096.
    Pubmed CrossRef
  35. Kearley J., Silver J.S., Sanden C., Liu Z., Berlin A.A., White N., Mori M., Pham T.H., Ward C.K., and Criner G.J., et al. (2015). Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42, 566-579.
    Pubmed CrossRef
  36. Kim C.H., Hashimoto-Hill S., and Kim M. (2016a). Migration and tissue tropism of innate lymphoid cells. Trends Immunol. 37, 68-79.
    Pubmed KoreaMed CrossRef
  37. Kim H.Y., DeKruyff R.H., and Umetsu D.T. (2010). The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat. Immunol. 11, 577-584.
    Pubmed KoreaMed CrossRef
  38. Kim H.Y., Lee H.J., Chang Y.J., Pichavant M., Shore S.A., Fitzgerald K.A., Iwakura Y., Israel E., Bolger K., and Faul J., et al. (2014). Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54-61.
    Pubmed KoreaMed CrossRef
  39. Kim H.Y., Umetsu D.T., and Dekruyff R.H. (2016b). Innate lymphoid cells in asthma: will they take your breath away? Eur. J. Immunol. 46, 795-806.
    Pubmed KoreaMed CrossRef
  40. Kim J., Chang Y., Bae B., Sohn K.H., Cho S.H., Chung D.H., Kang H.R., and Kim H.Y. (2019). Innate immune crosstalk in asthmatic airways: innate lymphoid cells coordinate polarization of lung macrophages. J. Allergy Clin. Immunol. 143, 1769-1782.e11.
    Pubmed CrossRef
  41. Kim M.H., Taparowsky E.J., and Kim C.H. (2015). Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut. Immunity 43, 107-119.
    Pubmed KoreaMed CrossRef
  42. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., Harrison O., and Powrie F. (2013). Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210, 917-931.
    Pubmed KoreaMed CrossRef
  43. Klose C.S., Kiss E.A., Schwierzeck V., Ebert K., Hoyler T., d'Hargues Y., Göppert N., Croxford A.L., Waisman A., and Tanriver Y., et al. (2013). A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature 494, 261-265.
    Pubmed CrossRef
  44. Kwong B., Rua R., Gao Y., Flickinger J. Jr., Wang Y. Jr., Kruhlak M.J. Jr., Zhu J. Jr., Vivier E. Jr., McGavern D.B. Jr., and Lazarevic V. Jr. (2017). T-bet-dependent NKp46(+) innate lymphoid cells regulate the onset of TH17-induced neuroinflammation. Nat. Immunol. 18, 1117-1127.
  45. Lambrecht B.N. and Hammad H. (2015). The immunology of asthma. Nat. Immunol. 16, 45-56.
    Pubmed CrossRef
  46. Lapidot T., Dar A., and Kollet O. (2005). How do stem cells find their way home? Blood 106, 1901-1910.
    Pubmed CrossRef
  47. Lim A.I. and Di Santo J.P. (2019). ILC-poiesis: ensuring tissue ILC differentiation at the right place and time. Eur. J. Immunol. 49, 11-18.
    Pubmed CrossRef
  48. Lim A.I., Menegatti S., Bustamante J., Le Bourhis L., Allez M., Rogge L., Casanova J.L., Yssel H., and Di Santo J.P. (2016). IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J. Exp. Med. 213, 569-583.
    Pubmed KoreaMed CrossRef
  49. Liu T., Barrett N.A., Kanaoka Y., Yoshimoto E., Garofalo D., Cirka H., Feng C., and Boyce J.A. (2018). Type 2 cysteinyl leukotriene receptors drive IL-33-dependent type 2 immunopathology and aspirin sensitivity. J. Immunol. 200, 915-927.
    Pubmed KoreaMed CrossRef
  50. Liu T., Wu J., Zhao J., Wang J., Zhang Y., Liu L., Cao L., Liu Y., and Dong L. (2015). Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir. Med. 109, 1391-1396.
    Pubmed CrossRef
  51. Long A., Dominguez D., Qin L., Chen S., Fan J., Zhang M., Fang D., Zhang Y., Kuzel T.M., and Zhang B. (2018). Type 2 innate lymphoid cells impede IL-33-mediated tumor suppression. J. Immunol. 201, 3456-3464.
    Pubmed KoreaMed CrossRef
  52. Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., Hardwigsen J., Anguiano E., Banchereau J., and Chaussabel D., et al. (2009). Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10, 75-82.
    Pubmed CrossRef
  53. Lund S.J., Portillo A., Cavagnero K., Baum R.E., Naji L.H., Badrani J.H., Mehta A., Croft M., Broide D.H., and Doherty T.A. (2017). Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation. J. Immunol. 199, 1096-1104.
    Pubmed KoreaMed CrossRef
  54. Male V., Nisoli I., Kostrzewski T., Allan D.S.J., Carlyle J.R., Lord G.M., Wack A., and Brady H.J.M. (2014). The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J. Exp. Med. 211, 635-642.
    Pubmed KoreaMed CrossRef
  55. Meininger I., Carrasco A., Rao A., Soini T., Kokkinou E., and Mjösberg J. (2020). Tissue-specific features of innate lymphoid cells. Trends Immunol. 41, 902-917.
    Pubmed CrossRef
  56. Mjösberg J. and Eidsmo L. (2014). Update on innate lymphoid cells in atopic and non-atopic inflammation in the airways and skin. Clin. Exp. Allergy 44, 1033-1043.
    Pubmed CrossRef
  57. Montaldo E., Juelke K., and Romagnani C. (2015). Group 3 innate lymphoid cells (ILC3s): origin, differentiation, and plasticity in humans and mice. Eur. J. Immunol. 45, 2171-2182.
    Pubmed CrossRef
  58. Monticelli L.A., Osborne L.C., Noti M., Tran S.V., Zaiss D.M., and Artis D. (2015). IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc. Natl. Acad. Sci. U. S. A. 112, 10762-10767.
    Pubmed KoreaMed CrossRef
  59. Monticelli L.A., Sonnenberg G.F., Abt M.C., Alenghat T., Ziegler C.G.K., Doering T.A., Angelosanto J.M., Laidlaw B.J., Yang C.Y., and Sathaliyawala T., et al. (2011). Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat. Immunol. 12, 1045-1054.
    Pubmed KoreaMed CrossRef
  60. Moral J.A., Leung J., Rojas L.A., Ruan J., Zhao J., Sethna Z., Ramnarain A., Gasmi B., Gururajan M., and Redmond D., et al. (2020). ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature 579, 130-135.
    Pubmed KoreaMed CrossRef
  61. Morita H., Kubo T., Rückert B., Ravindran A., Soyka M.B., Rinaldi A.O., Sugita K., Wawrzyniak M., Wawrzyniak P., and Motomura K., et al. (2019). Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J. Allergy Clin. Immunol. 143, 2190-2201.e9.
    Pubmed CrossRef
  62. Morita H., Moro K., and Koyasu S. (2016). Innate lymphoid cells in allergic and nonallergic inflammation. J. Allergy Clin. Immunol. 138, 1253-1264.
    Pubmed CrossRef
  63. Moro K., Kabata H., Tanabe M., Koga S., Takeno N., Mochizuki M., Fukunaga K., Asano K., Betsuyaku T., and Koyasu S. (2016). Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17, 76-86.
    Pubmed CrossRef
  64. Ni L. and Dong C. (2018). Roles of myeloid and lymphoid cells in the pathogenesis of chronic obstructive pulmonary disease. Front. Immunol. 9, 1431.
    Pubmed KoreaMed CrossRef
  65. O'Sullivan T.E. (2019). Dazed and confused: NK cells. Front. Immunol. 10, 2235.
    Pubmed KoreaMed CrossRef
  66. Panda S.K. and Colonna M. (2019). Innate lymphoid cells in mucosal immunity. Front. Immunol. 10, 861.
    Pubmed KoreaMed CrossRef
  67. Park S.M., Do-Thi V.A., Lee J.O., Lee H., and Kim Y.S. (2020). Interleukin-9 inhibits lung metastasis of melanoma through stimulating anti-tumor M1 macrophages. Mol. Cells 43, 479-490.
    Pubmed KoreaMed CrossRef
  68. Patman G. (2015). Immunology: gut migration of innate lymphoid cells. Nat. Rev. Gastroenterol. Hepatol. 12, 430.
    Pubmed CrossRef
  69. Perry J.S., Han S., Xu Q., Herman M.L., Kennedy L.B., Csako G., and Bielekova B. (2012). Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci. Transl. Med. 4, 145ra106.
    Pubmed KoreaMed CrossRef
  70. Peters C.P., Mjosberg J.M., Bernink J.H., and Spits H. (2016). Innate lymphoid cells in inflammatory bowel diseases. Immunol. Lett. 172, 124-131.
    Pubmed CrossRef
  71. Possot C., Schmutz S., Chea S., Boucontet L., Louise A., Cumano A., and Golub R. (2011). Notch signaling is necessary for adult, but not fetal, development of RORgammat(+) innate lymphoid cells. Nat. Immunol. 12, 949-958.
  72. Rabe K.F. and Watz H. (2017). Chronic obstructive pulmonary disease. Lancet 389, 1931-1940.
    Pubmed CrossRef
  73. Reich D.S., Lucchinetti C.F., and Calabresi P.A. (2018). Multiple sclerosis. N. Engl. J. Med. 378, 169-180.
    Pubmed KoreaMed CrossRef
  74. Salimi M., Stoger L., Liu W., Go S., Pavord I., Klenerman P., Ogg G., and Xue L. (2017). Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J. Allergy Clin. Immunol. 140, 1090-1100.e11.
    Pubmed KoreaMed CrossRef
  75. Saranchova I., Han J., Zaman R., Arora H., Huang H., Fenninger F., Choi K.B., Munro L., Pfeifer C.G., and Welch I., et al. (2018). Type 2 innate lymphocytes actuate immunity against tumours and limit cancer metastasis. Sci. Rep. 8, 2924.
    Pubmed KoreaMed CrossRef
  76. Scandella E., Bolinger B., Lattmann E., Miller S., Favre S., Littman D.R., Finke D., Luther S.A., Junt T., and Ludewig B. (2008). Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat. Immunol. 9, 667-675.
    Pubmed CrossRef
  77. Scanlon S.T. and McKenzie A.N. (2012). Type 2 innate lymphoid cells: new players in asthma and allergy. Curr. Opin. Immunol. 24, 707-712.
    Pubmed CrossRef
  78. Serafini N., Klein Wolterink R.G., Satoh-Takayama N., Xu W., Vosshenrich C.A., Hendriks R.W., and Di Santo J.P. (2014). Gata3 drives development of RORgammat+ group 3 innate lymphoid cells. J. Exp. Med. 211, 199-208.
  79. Silver J.S., Kearley J., Copenhaver A.M., Sanden C., Mori M., Yu L., Pritchard G.H., Berlin A.A., Hunter C.A., and Bowler R., et al. (2016). Inflammatory triggers associated with exacerbations of COPD orchestrate plasticity of group 2 innate lymphoid cells in the lungs. Nat. Immunol. 17, 626-635.
    Pubmed KoreaMed CrossRef
  80. Smith S.G., Chen R., Kjarsgaard M., Huang C., Oliveria J.P., O'Byrne P.M., Gauvreau G.M., Boulet L.P., Lemiere C., and Martin J., et al. (2016). Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J. Allergy Clin. Immunol. 137, 75-86.e8.
    Pubmed CrossRef
  81. Spits H. and Cupedo T. (2012). Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu. Rev. Immunol. 30, 647-675.
    Pubmed CrossRef
  82. Suzuki M., Sze M.A., Campbell J.D., Brothers J.F., Lenburg M.E., McDonough J.E., Elliott W.M., Cooper J.D., Spira A., and Hogg J.C. (2017). The cellular and molecular determinants of emphysematous destruction in COPD. Sci. Rep. 7, 9562.
    Pubmed KoreaMed CrossRef
  83. Tanriver Y. and Diefenbach A. (2014). Transcription factors controlling development and function of innate lymphoid cells. Int. Immunol. 26, 119-128.
    Pubmed CrossRef
  84. Trabanelli S., Chevalier M.F., Martinez-Usatorre A., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., and Papayannidis C., et al. (2017). Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat. Commun. 8, 593.
    Pubmed KoreaMed CrossRef
  85. van de Pavert S.A., Olivier B.J., Goverse G., Vondenhoff M.F., Greuter M., Beke P., Kusser K., Höpken U.E., Lipp M., and Niederreither K., et al. (2009). Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation. Nat. Immunol. 10, 1193-1199.
    Pubmed KoreaMed CrossRef
  86. Vivier E., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., Koyasu S., Locksley R.M., McKenzie A.N.J., and Mebius R.E., et al. (2018). Innate lymphoid cells: 10 years on. Cell 174, 1054-1066.
    Pubmed CrossRef
  87. Walker J.A., Clark P.A., Crisp A., Barlow J.L., Szeto A., Ferreira A.C.F., Rana B.M.J., Jolin H.E., Rodriguez-Rodriguez N., and Sivasubramaniam M., et al. (2019). Polychromic reporter mice reveal unappreciated innate lymphoid cell progenitor heterogeneity and elusive ILC3 progenitors in bone marrow. Immunity 51, 104-118.e7.
    Pubmed KoreaMed CrossRef
  88. Wan J., Wu Y., Huang L., Tian Y., Ji X., Abdelaziz M.H., Cai W., Dineshkumar K., Lei Y., and Yao S., et al. (2021). ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett. 502, 34-43.
    Pubmed CrossRef
  89. Wang S., Xia P., Chen Y., Qu Y., Xiong Z., Ye B., Du Y., Tian Y., Yin Z., and Xu Z., et al. (2017). Regulatory innate lymphoid cells control innate intestinal inflammation. Cell 171, 201-216.e18.
    Pubmed CrossRef
  90. Wills-Karp M. and Finkelman F.D. (2011). Innate lymphoid cells wield a double-edged sword: type 2 cytokine-producing innate lymphoid cells are present in human and mouse lungs, where they contribute to both type 2 immune responses and tissue repair. Nat. Immunol. 12, 1025-1028.
  91. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., and Sabat R. (2004). IL-22 increases the innate immunity of tissues. Immunity 21, 241-254.
    Pubmed CrossRef
  92. Wolterink R.G., KleinJan A., van Nimwegen M., Bergen I., de Bruijn M., Levani Y., and Hendriks R.W. (2012). Pulmonary innate lymphoid cells are major producers of IL‐5 and IL‐13 in murine models of allergic asthma. Eur. J. Immunol. 42, 1106-1116.
  93. Xu W., Domingues R.G., Fonseca-Pereira D., Ferreira M., Ribeiro H., Lopez-Lastra S., Motomura Y., Moreira-Santos L., Bihl F., and Braud V., et al. (2015). NFIL3 orchestrates the emergence of common helper innate lymphoid cell precursors. Cell Rep. 10, 2043-2054.
    Pubmed CrossRef
  94. Yagi R., Zhong C., Northrup D.L., Yu F., Bouladoux N., Spencer S., Hu G., Barron L., Sharma S., and Nakayama T., et al. (2014). The transcription factor GATA3 is critical for the development of all IL-7Ralpha-expressing innate lymphoid cells. Immunity 40, 378-388.
  95. Zeng B., Shi S., Ashworth G., Dong C., Liu J., and Xing F. (2019). ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis. 10, 315.
    Pubmed KoreaMed CrossRef
  96. Zlotoff D.A., Sambandam A., Logan T.D., Bell J.J., Schwarz B.A., and Bhandoola A. (2010). CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus. Blood 115, 1897-1905.
    Pubmed KoreaMed CrossRef
  97. Zook E.C. and Kee B.L. (2016). Development of innate lymphoid cells. Nat. Immunol. 17, 775-782.
    Pubmed CrossRef
Mol. Cells
Sep 30, 2023 Vol.46 No.9, pp. 527~572
COVER PICTURE
Chronic obstructive pulmonary disease (COPD) is marked by airspace enlargement (emphysema) and small airway fibrosis, leading to airflow obstruction and eventual respiratory failure. Shown is a microphotograph of hematoxylin and eosin (H&E)-stained histological sections of the enlarged alveoli as an indicator of emphysema. Piao et al. (pp. 558-572) demonstrate that recombinant human hyaluronan and proteoglycan link protein 1 (rhHAPLN1) significantly reduces the extended airspaces of the emphysematous alveoli by increasing the levels of TGF-β receptor I and SIRT1/6, as a previously unrecognized mechanism in human alveolar epithelial cells, and consequently mitigates COPD.
Current Issue Archives

Share this article on

  • line

Related articles in Mol. Cells

Molecules and Cells

eISSN 0219-1032
qr-code Download